published_or_final_version / abstract / toc / Pharmacology / Master / Master of Philosophy

No description available.

Nitric oxide synthase (NOS) catalyses the production of nitric oxide (NO). A cytochrome P450-like oxygenase, it uses two monooxygenation steps to convert L-arginine (L-arg) first to N -hydroxy-L-arginine (NOHA), a stable intermediate, and then to L-citrulline and NO. Mammalian NOSs are homodimeric enzymes. Each monomer is composed of an oxygenase domain (containing the L-arg binding site, a heme ligated by a cysteine thiolate, and a tetrahydrobiopterin (H4B)) and a reductase domain (binding NADPH, FAD, and FMN). NOS substrates are O2, L-arg, and NADPH. NADPH is the source of electrons required for oxygen activation. H4B is a vital cofactor that aids dimerisation and acts as a reducing/oxidising agent. Controversy still exists as to the final oxygenating species in the NOS mechanism, but the general reaction scheme is known. The ferric heme is reduced to the ferrous state by an electron from the reductase domain. Then oxygen binds to form the oxy-ferrous species. Then H4B donates an electron to form a peroxy-ferric species. It is likely this then forms a compound 1 (Fe(IV)+.=O) species that is the final oxygenating species. This thesis probes the mechanism of NOS to further define the mechanistic intermediates involved. The role of H4B in NO synthesis has been probed in both normal turnover conditions and special case reactions. To elucidate this mechanism further a mutant with a residue capable of stabilising the activated oxygen species was created, G586S, where glycine 586 of nNOS was replaced with a serine. This serine was within hydrogen bonding distance of the oxy-heme. A stabilised intermediate was observed by stopped flow reaction in the presence of H4B, but not aH4B (an inactive pterin analogue). Here single turnover reactions, each following either the reaction of L-arg to NOHA or NOHA to citrulline, were performed on the mutant using an external source of electrons. The reaction products were observed by HPLC. The mutant appears capable of the conversion of NOHA to citrulline, but not L-arg to NOHA. The WT enzyme appears capable of both. The intermediate is observed with either L-arg or NOHA bound, suggesting both reactions proceed via the same active oxygenating species. The inability of the mutant to catalyse the conversion of L-arg to NOHA may be due to protonation of the substrate hindering reaction such that the active oxygenating species decays before reaction can occur. This mutation, in allowing separation of the two monooxygenation steps, deserves further study. H4B binds at the dimer interface of NOS. Here the -systems of the pterins are only 13Å apart. This is within allowed distances for efficient electron transfer. Electron transfer between hemes, via the pterins, would allow a route for the breakdown of a dead end, ferrous-NO, species. Stopped flow monitoring of the decay of the ferrous-heme NO complex with nNOSoxy dimers with varying proportions of the hemes in the ferrous heme-NO complex showed no electron transfer between hemes of the dimer. The rate of decay of the ferrous heme-NO complex in oxygenated buffer is 0.12 s-1 for all conditions tested here. H4B-deficiency leads to several diseases. H4B makes a poor drug due to instability and cost, the search for druggable analogues of it is ongoing. H4B analogues blocked at the 6,7-positions in the dihydropterine-form have been screened here for catalytic activity. Several have shown comparable ability to catalyse NO production in vitro. Structure function analysis of these analogues has revealed the extent extension is tolerated at the C6 and C7 positions of the pterin.

Calmodulin (CaM) is a calcium-binding protein that has promiscuous regulatory interactions with over three hundred intracellular protein targets. The focus of this study was to characterize the functional role of phosphorylated CaM in vitro and calcium-deficient CaM (Apo-CaM) ex vivo. In the in vitro study, the effect of phosphorylated CaM on the binding and activation of CaM target proteins was analyzed using mammalian Nitric Oxide Synthase (NOS). NOS is an enzyme that catalyzes the conversion of L-arginine to L-citrulline and •NO. In addition, the activation of NOS by modified CaM proteins was also analyzed in the presence of a CaM binding peptide, PEP-19. Protein trafficking experiments were performed ex vivo to extend our understanding of Apo-CaM’s functional role in mammalian cells. The cell lines that were used in this investigation include mouse Embryonic Stem Cells (mESC), Human Umbilical Vein Endothelia Cells (HUVEC) and Human Neuronal Glioma Cells (HNGC). The major finding of this projects are: phosphorylation of selective CaM residues can attenuated NOS activity, electrostatic interactions are important in the activation of iNOS by CaM, and the activation of iNOS by CaM occurs in a calcium-dependent manner

Calmodulin (CaM) is a calcium-binding protein that has promiscuous regulatory interactions with over three hundred intracellular protein targets. The focus of this study was to characterize the functional role of phosphorylated CaM in vitro and calcium-deficient CaM (Apo-CaM) ex vivo. In the in vitro study, the effect of phosphorylated CaM on the binding and activation of CaM target proteins was analyzed using mammalian Nitric Oxide Synthase (NOS). NOS is an enzyme that catalyzes the conversion of L-arginine to L-citrulline and •NO. In addition, the activation of NOS by modified CaM proteins was also analyzed in the presence of a CaM binding peptide, PEP-19. Protein trafficking experiments were performed ex vivo to extend our understanding of Apo-CaM’s functional role in mammalian cells. The cell lines that were used in this investigation include mouse Embryonic Stem Cells (mESC), Human Umbilical Vein Endothelia Cells (HUVEC) and Human Neuronal Glioma Cells (HNGC). The major finding of this projects are: phosphorylation of selective CaM residues can attenuated NOS activity, electrostatic interactions are important in the activation of iNOS by CaM, and the activation of iNOS by CaM occurs in a calcium-dependent manner

Thesis (M.S.)--Cleveland State University, 2008. / Abstracts. Title from PDF t.p. (viewed on Jan. 29, 2009). Includes bibliographical references (p. 33-36). Available online via the OhioLINK ETD Center. Also available in print.

Thesis (Ph. D.)--Ohio State University, 2003. / Title from first page of PDF file. Document formatted into pages; contains xii, 152 p.; also includes graphics (some col.). Includes bibliographical references (p. 137-150). Available online via OhioLINK's ETD Center

No description available.

No description available.

Master of Science / Department of Kinesiology / Brett J. Wong / Nitrate supplementation in the form of beetroot juice (BRJ) has been shown to increase nitric oxide (NO), where nitrate can be reduced to nitrite and NO through both nitric oxide synthase (NOS) independent and dependent pathways. We tested the hypothesis that BRJ would augment the NO component of cutaneous thermal hyperemia. Dietary intervention consisted of one shot of BRJ for three days. Six subjects were equipped with two microdialysis fibers on the ventral forearm and randomly assigned to lactated Ringer’s (control) or continuous infusion of 20mM L-NAME (NOS inhibitor). The control site was subsequently perfused with L-NAME once a plateau in the local heating response was achieved to quantify NOS-dependent cutaneous vasodilation. Skin blood flow via laser-Doppler flowmetry (LDF) and mean arterial pressure (MAP) were measured; cutaneous vascular conductance (CVC) was calculated as LDF/MAP and normalized to %CVCmax. Maximal vasodilation was achieved via local heating to 43°C and 54mM sodium nitroprusside infusion. There was a significant decrease in DBP after BRJ (Pre-BRJ:74 ± 1 mmHg vs. Post-BRJ: 61 ± 2 mmHg; p < 0.05) and significant reduction in MAP after BRJ (Pre-BRJ: 90 ± 1 mmHg vs. Post-BRJ: 80 ± 2 mmHg; p < 0.05). The initial peak and secondary plateau phase of cutaneous thermal hyperemia were attenuated at sites with continuous LNAME; however, there was no effect of BRJ on either the initial peak at control sites (Pre-BRJ: 76 ± 3%CVCmax vs. Post-BRJ: 75 ± 4%CVCmax) or L-NAME sites (Pre-BRJ: 60 ± 4%CVCmax vs. Post-BRJ: 59 ± 5%CVCmax) or the secondary plateau phaseat control sites (Pre-BRJ: 88 ± 4%CVCmax vs. Post-BRJ: 90 ± 4%CVCmax) or L-NAME sites (Pre-BRJ: 45 ± 5%CVCmax vs. Post-BRJ: 51 ± 3%CVCmax). The decrease in %CVCmax to L-NAME infusion during the plateau of local heating (i.e. post-L-NAME drop) was greater after BRJ (Pre-BRJ: 36 ± 2%CVCmax vs. Post-BRJ: 28 ± 1%CVCmax; p < 0.05). This resulted in a greater contribution of NOS to the plateau phase of local heating (Pre-BRJ: 57±3%CVCmax vs. Post-BRJ: 64±2%CVCmax; p < 0.05). These data suggest BRJ modestly improves NOS-dependent vasodilation to local heating in the cutaneous vasculature of healthy humans.